WilmerHale is a sponsor of the American Conference Institute’s (ACI) 10th Anniversary Paragraph IV Disputes Master Symposium from October 15-16 in Chicago, Illinois. Each fall, ACI brings leading pharmaceutical patent litigators for brand name and generic drug companies together to receive the latest updates on Hatch-Waxman litigation and engage in peer networking opportunities.
On October 15, WilmerHale Partner Kevin Prussia will present as part of the “Examining the Use of Clinical Trials as Prior Art” session, a panel discussion exploring best practices for managing disclosures and protecting IP amid innovators’ concerns over clinical trials being used against them as prior art.
